Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
913088-80-9
Molecular formula
C10H10ClN5O2
Molecular weight
267.67 g/mol
Drug class
Antiseizure medicinevoltage-gated sodium-channel modulator and positive allosteric GABAA receptor modulator
Mechanism of action
Reduces repetitive neuronal firing by inhibiting persistent sodium currents and can enhance inhibitory signalling through positive allosteric modulation of GABAA receptors. The relative contribution of these actions to clinical antiseizure effects is not fully defined.
Indications / reported uses
Treatment of partial-onset (focal) seizures in adults; use requires gradual dose titration because of serious hypersensitivity and other safety risks
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Cenobamate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cenobamate Permitted Daily Exposure (PDE) report (the Cenobamate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cenobamate Occupational Exposure Limit (OEL) report (the Cenobamate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.